TNF and ulcerative colitis: At the end of the second week, 19.1% of vedolizumab-treated ulcerative colitis (UC) patients had favorable rectal bleeding and stool frequency scores. The placebo group had 10% overall and 6.6% TNF antagonist naïve. In TNF antagonist-naive patients with Crohn's disease (CD), vedolizumab showed higher response rates for abdominal pain and stool frequency at both week 2 (15.0% vs. 7.9% on placebo) and week 4 (23.8% vs. 10.3% on placebo).